Dr Robert Grundy has spent over 20 years in Pharma and Biotech which began in drug discovery and development at Schering-Plough and GlaxoSmithKline. Rob served as Chief Scientific Officer with Cerebricon before becoming a founding member of Almac Discovery in 2008, contributing significantly to the establishment and growth of the business, building a pipeline of oncology therapeutic assets through licensing and strategic partnerships. In 2014 Rob founded Anglezarke Life Sciences Ltd, a business development, commercialization and growth strategy consultancy in the Life Sciences sector. Rob has also served as CEO of ReVana Therapeutics, CIGA Healthcare and Health Innovation Research Alliance Northern Ireland. Rob serves as an advisor to industry, academia and government which includes key economic advisory roles in the Northern Ireland Government.
Rob has PhD in Neuroscience from Manchester University, an Honours degree in Pharmacology from Liverpool University and has held honorary lectureships at King’s College London and Queen’s University Belfast.